Celldex Therapeutics, Inc. — Director's Dealing 2025

Nov 12, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2025-11-10

Reporting Person: Lawver Teri L (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-11-10	ISO (right to buy)	$22.67	A	100000	Acquired	2035-11-10	Common Stock (100000)	Direct

Footnotes

F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F2: 25% vest on November 10, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.